TJ272B - Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition - Google Patents

Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition

Info

Publication number
TJ272B
TJ272B TJ96000367A TJ96000367A TJ272B TJ 272 B TJ272 B TJ 272B TJ 96000367 A TJ96000367 A TJ 96000367A TJ 96000367 A TJ96000367 A TJ 96000367A TJ 272 B TJ272 B TJ 272B
Authority
TJ
Tajikistan
Prior art keywords
compounds
quinazoline compounds
pharmaceutical
acceptable salts
pharmaceutical composition
Prior art date
Application number
TJ96000367A
Other languages
English (en)
Inventor
Stephen Webber
Ted M Bleckman
John Attard
Terence R Jones
Michael D Varney
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of TJ272B publication Critical patent/TJ272B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TJ96000367A 1992-03-31 1993-03-26 Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition TJ272B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/861,030 US5430148A (en) 1992-03-31 1992-03-31 Antiproliferative quinazolines
PCT/US1993/002636 WO1993020055A1 (en) 1992-03-31 1993-03-26 Antiproliferative quinazolines

Publications (1)

Publication Number Publication Date
TJ272B true TJ272B (en) 2000-10-05

Family

ID=25334675

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000367A TJ272B (en) 1992-03-31 1993-03-26 Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition

Country Status (20)

Country Link
US (3) US5430148A (de)
EP (1) EP0637300B1 (de)
JP (1) JP3272357B2 (de)
KR (1) KR100226114B1 (de)
AT (1) ATE205197T1 (de)
AU (1) AU681075B2 (de)
CA (2) CA2474211C (de)
DE (1) DE69330715T2 (de)
DK (1) DK0637300T3 (de)
ES (1) ES2162818T3 (de)
FI (1) FI113765B (de)
HU (1) HU222523B1 (de)
MD (1) MD1638G2 (de)
NO (1) NO307829B1 (de)
NZ (1) NZ251804A (de)
PT (1) PT637300E (de)
RU (1) RU2135481C1 (de)
SG (2) SG46672A1 (de)
TJ (1) TJ272B (de)
WO (1) WO1993020055A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5593999A (en) * 1995-06-07 1997-01-14 Nair; Madhavan G. Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
AU2769897A (en) * 1996-05-07 1997-11-26 Basf Aktiengesellschaft Imidazoquinazolines, agents containing them and their use to combat fungi and animal pests
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ATE413881T1 (de) * 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
ATE212661T1 (de) 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2378187C (en) 1999-07-22 2011-09-13 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
BR0114713A (pt) * 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US6486199B1 (en) 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA04011074A (es) * 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
EP1513820A4 (de) * 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
CA2489367A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
WO2005061460A1 (en) * 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
EP2161275A1 (de) * 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs aus 2,4-Pyrimidindiamin-Verbindungen und ihre Verwendungen
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
CN1303080C (zh) * 2005-07-18 2007-03-07 康辰医药发展有限公司 盐酸洛拉曲克的合成工艺
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CN101353343B (zh) * 2007-07-27 2012-07-04 上海医药工业研究院 高纯度盐酸诺拉曲塞二水合物的制备方法
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US20120122819A1 (en) * 2009-06-12 2012-05-17 Socpra - Sciences Et Genie S.E.C. Guanine riboswitch binding compounds and their use as antibiotics
KR101891834B1 (ko) 2009-12-18 2018-09-28 바실리어 파마슈티카 아게 트리시클릭 항생제
US9321788B2 (en) 2011-06-17 2016-04-26 Basilea Pharmaceutica Ag Tricyclic antibiotics
RU2507199C1 (ru) * 2012-09-10 2014-02-20 Владимир Иванович Петров Производные хиназолина, обладающие антидепрессивной, анксиолитической и ноотропной активностью
RU2507198C1 (ru) * 2012-09-10 2014-02-20 Владимир Иванович Петров Производные хиназолина, обладающие ноотропной и антигипоксической активностью
RU2622638C1 (ru) * 2016-07-14 2017-06-19 Владимир Иванович Петров Производные хиназолин-4(3н)-она, обладающие нейро- и кардиопротекторной активностью
CN113727733B (zh) 2019-02-14 2023-01-24 索姆创新生物技术公司 用于治疗苯丙酮尿症的氨苯蝶啶或诺拉曲塞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1817982A (en) * 1931-08-11 Winfrid hentrich and max habdtmann
CA793845A (en) * 1968-09-03 Davoll John Amine compounds and production thereof
GB206565A (en) * 1922-08-03 1923-11-05 Walter Wood Tullis Improvements in or relating to the concentration and preparation for smelting of iron ores
GB1045180A (en) * 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
GB1212613A (en) * 1967-02-28 1970-11-18 Chinoin Gyogyszer Es Vegyeszet 4-quinazolone derivatives and process for the preparation thereof
GB1161644A (en) * 1967-09-11 1969-08-13 Parke Davis & Co Quinazoline Compounds and process means for producing the same
US4048312A (en) * 1973-10-30 1977-09-13 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
US4223143A (en) * 1978-12-11 1980-09-16 Siegfried Aktiengesellschaft Quinazoline derivatives
US4391809A (en) * 1979-10-15 1983-07-05 Warner-Lambert Company Methods for treating psoriasis
EP0031237B1 (de) * 1979-12-19 1984-10-17 National Research Development Corporation Chinazolinderivate, Verfahren zu ihrer Herstellung, sie enthaltende Zusammensetzungen und ihre Verwendung als Anti-Krebs-Mittel
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
JPS57156467A (en) * 1981-03-20 1982-09-27 Asahi Chem Ind Co Ltd 2,4-disubstituted-6-quinazolinesulfonamide derivative
JPS6136273A (ja) * 1984-07-26 1986-02-20 Mitsubishi Yuka Yakuhin Kk ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体
US4749698A (en) * 1985-07-08 1988-06-07 Rorer Pharmaceutical Corporation Antihypertensive derivatives
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8809978D0 (en) * 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
EP0365763A1 (de) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Zyklische Verbindungen als Antiproleferahne
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
AU640016B2 (en) * 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines

Also Published As

Publication number Publication date
NO307829B1 (no) 2000-06-05
MD1638F2 (en) 2001-03-31
NZ251804A (en) 1997-06-24
JPH07505395A (ja) 1995-06-15
EP0637300B1 (de) 2001-09-05
FI944525A (fi) 1994-09-29
NO943629L (no) 1994-09-29
SG46672A1 (en) 1998-02-20
JP3272357B2 (ja) 2002-04-08
CA2474211C (en) 2006-10-03
US5430148A (en) 1995-07-04
DE69330715T2 (de) 2002-02-14
NO943629D0 (no) 1994-09-29
US5707992A (en) 1998-01-13
ES2162818T3 (es) 2002-01-16
US5885996A (en) 1999-03-23
SG93183A1 (en) 2002-12-17
ATE205197T1 (de) 2001-09-15
DE69330715D1 (de) 2001-10-11
PT637300E (pt) 2002-01-30
WO1993020055A1 (en) 1993-10-14
FI113765B (fi) 2004-06-15
MD1638G2 (ro) 2001-09-30
HU9402799D0 (en) 1994-12-28
HU222523B1 (hu) 2003-08-28
CA2474211A1 (en) 1993-10-14
DK0637300T3 (da) 2001-12-10
CA2132514C (en) 2004-10-26
AU3966493A (en) 1993-11-08
KR100226114B1 (ko) 1999-10-15
EP0637300A1 (de) 1995-02-08
AU681075B2 (en) 1997-08-21
CA2132514A1 (en) 1993-10-14
HUT68580A (en) 1995-06-28
RU94045251A (ru) 1996-07-20
FI944525A0 (fi) 1994-09-29
RU2135481C1 (ru) 1999-08-27

Similar Documents

Publication Publication Date Title
TJ272B (en) Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
CA2236160A1 (en) Method and composition for inhibiting growth of microorganisms including peracetic acid and a non-oxidizing biocide
CA2190324A1 (en) Method and Composition for Inhibiting Growth of Microorganisms Including Peracetic Acid and a Non-Oxidizing Biocide
CA2334907A1 (en) Method and composition for inhibiting growth of microorganisms including peracetic acid and a non-oxidizing biocide
PL316033A1 (en) Acidified nitrite as an agent against micro-organisms
WO2000034265A3 (en) Quinoline-indole antimicrobial agents
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MXPA02012326A (es) Peptidos quimicamente modificados, composiciones y metodos para su produccion y uso.
AU1120888A (en) Biocidal compositions and use thereof
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
WO1999067238A3 (en) Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
AU2267899A (en) Fungi of the genus piriformospora
EP0333000A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
ZA933251B (en) Halogenated 4'-methozyacetophenones as microbicides and preservatives
CA2335397A1 (en) A method for screening compounds for their potential to inhibit neoplasia and pharmaceutical compositions containing such compounds
EP0332999A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
WO1987001279A3 (en) Antitumor chamigrene derivatives and their methods of use
MX9603754A (es) Compuestos, de amplio espectro, activos contra microbios.
MX9603535A (es) Nitrito acido como un agente antimicrobiano.
NZ500671A (en) Stable crystalline hydrochloride and hydrobromide salts of swainsonine and use in the treatment of fungal, bacterial and viral diseases
RU93005169A (ru) Производные замещенного нафталина, способ их получения, фармацевтическая композиция и способ лечения
ATE53922T1 (de) Synergistische, antimikrobische beimischungen, enthaltend 2-bromo-2-bromomethylglutaronitril, verfahren zur hemmung mikrobischen wachstums und gegen mikrobisches wachstum geschuetzte substrate.